AKARNA THERAPEUTICS LTD has a total of 85 patent applications. It decreased the IP activity by 56.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, Australia and Singapore. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CALCIMEDICA INC, TEREVANS INK and ACEA PHARM INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | Australia | 9 | |
#3 | Singapore | 9 | |
#4 | China | 7 | |
#5 | EPO (European Patent Office) | 7 | |
#6 | Brazil | 6 | |
#7 | Canada | 6 | |
#8 | Israel | 6 | |
#9 | Republic of Korea | 6 | |
#10 | WIPO (World Intellectual Property Organization) | 6 | |
#11 | Mexico | 5 | |
#12 | Chile | 3 | |
#13 | Hong Kong | 2 | |
#14 | Colombia | 1 | |
#15 | Japan | 1 | |
#16 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Mohan Raju | 67 |
#2 | Pratt Benjamin Anthony | 60 |
#3 | Raju Mohan | 12 |
#4 | Benjamin Anthony Pratt | 12 |
#5 | Pratt Benjamin | 6 |
#6 | Pratt Benjamin Antony | 1 |
Publication | Filing date | Title |
---|---|---|
AU2018275674A1 | Fused bicyclic compounds | |
EP3463373A1 | Combination therapies with farnesoid x receptor (fxr) modulators | |
CN109789149A | For treating the fused bicyclic compound of disease | |
CN107912042A | For treating the fused bicyclic compound of disease | |
CA2971755A1 | Fused bicyclic compounds for the treatment of disease | |
AU2015349687A1 | Fused bicyclic compounds for the treatment of disease |